Answers are grounded in this paper and cite their sources.
The synthesis of potassium (η2-4-allyl-2-methoxyphenol)trichloridoplatinate(II), K[PtCl3(C10H12O2)], (1), starting from Zeise's salt and Ocimum sanctum L. oil has been optimized. Starting from (1), three new platinum(II) complexes, namely (η2-4-allyl-2-methoxyphenol)chlorido(2-methylquinolin-8-olato-κ2 N,O)platinum(II), (2), (η2-4-allyl-2-methoxyphenol)chlorido(5-nitroquinolin-8-olato-κ2 N,O)platinum(II), (3), and (η2-4-allyl-2-methoxyphenol)chlorido(5,7-dichloroquinolin-8-olato-κ2 N,O)platinum(II), [Pt(C9H4Cl2NO)Cl(C10H12O2)], (4), containing eugenol and a quinolin-8-ol derivative (R-OQ), have been synthesized and characterized by elemental analyses, MS, IR, 1H NMR and NOESY spectra. For (1) and (4), single-crystal X-ray diffraction studies were also carried out. Complexes (2)–(4) show good inhibiting abilities on three human cancer cell lines, i.e. KB, Hep-G2 and LU, with IC50 values of 1.42–17.8 µM. Complex (3) gives an impressively high activity against KB, Hep-G2, LU and MCF-7, with IC50 values of 1.42–4.91 µM, which are much lower than those of cisplatin and some other platinum(II) complexes.
No takes yet. Share an insight, caveat, or question.
Thanh et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: